Prof. Yinghong Shi 史颖弘
Chief Physician, Professor
Department of Hepatobiliary Oncology and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and surgical treatment of liver tumors, prevention of postoperative metastasis and recurrence, comprehensive treatment of biliary tract tumors, and liver transplantation.
Dr. Shi is Chief Physician and Professor at Zhongshan Hospital, Fudan University, serving as Deputy Director of the Liver Surgery Department. Research includes tumor cell death and liver cancer metastasis at the University of Pittsburgh (2005) and living donor liver transplantation at Kaohsiung Chang Gung Memorial Hospital (2007). Performs approximately 350 liver resections and 50 liver transplants annually.
Professional roles
- Member, Chinese Medical Association
- Youth Committee Member, Oncology Branch, Chinese Medical Association
- Deputy Leader, Early Diagnosis and Treatment Group, Oncology Branch, Chinese Medical Association
- Member, Transplant Immunology Committee, Organ Transplantation Professional Committee, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Shi Yinghong). Papers usually list the name as Yinghong Shi or Shi Y.
Selected publications
204 papers on PubMed matched by name and affiliation; 40 as first or senior author since 2016. Most recent first- or senior-author papers:
- RSC Adv, 2026 (first author): Synthetic oxygen carriers as substitutes of red blood cells for blood transfusion. PubMed 42558933
- Discov Oncol, 2026 (senior author): Radiogenomics deciphers tumor heterogeneity in hepatocellular carcinoma and combined hepatocellular-cholangiocarcinoma. PubMed 42101525
- Adv Sci (Weinh), 2026 (senior author): DNMT2-m5C-ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation-Mediated Notch Pathway. PubMed 41417568
- Cell Death Dis, 2025 (senior author): Targeting CREB3L2-mediated lipid metabolism overcomes lenvatinib resistance and attenuates the progression of hepatocellular carcinoma. PubMed 41285809
- Hepatol Int, 2025 (senior author): Predictive value of neutrophil-to-lymphocyte ratio in recurrent HCC after repeat hepatectomy or salvage liver transplantation. PubMed 39985654
- Nat Commun, 2025 (senior author): Metabolism archetype cancer cells induce protumor TREM2(+) macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma. PubMed 40695827
- Lancet Gastroenterol Hepatol, 2025 (first author): Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial. PubMed 40409323
- Sci Adv, 2025 (senior author): Targeting HMGB2 acts as dual immunomodulator by bolstering CD8(+) T cell function and inhibiting tumor growth in hepatocellular carcinoma. PubMed 40315321
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion